CY1108676T1 - Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων - Google Patents
Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχωνInfo
- Publication number
- CY1108676T1 CY1108676T1 CY20081101427T CY081101427T CY1108676T1 CY 1108676 T1 CY1108676 T1 CY 1108676T1 CY 20081101427 T CY20081101427 T CY 20081101427T CY 081101427 T CY081101427 T CY 081101427T CY 1108676 T1 CY1108676 T1 CY 1108676T1
- Authority
- CY
- Cyprus
- Prior art keywords
- ophthalmic
- poloxamine
- tonikotitas
- glykolis
- medicament
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 229940023490 ophthalmic product Drugs 0.000 title abstract 2
- 229920001987 poloxamine Polymers 0.000 title abstract 2
- 239000003732 agents acting on the eye Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940100654 ophthalmic suspension Drugs 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000007900 aqueous suspension Substances 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002736 nonionic surfactant Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67951005P | 2005-05-10 | 2005-05-10 | |
| EP06759259A EP1906916B1 (en) | 2005-05-10 | 2006-05-08 | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108676T1 true CY1108676T1 (el) | 2014-04-09 |
Family
ID=37087751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101427T CY1108676T1 (el) | 2005-05-10 | 2008-12-10 | Οφθαλμικο εναιωρημα περιλαμβανον ενα οφθαλμικο φαρμακο, μια πολοξαμινη και εναν παραγοντα ρυθμισεως της τονικοτητας τυπου γλυκολης, χρηση της εν λογω συνθεσεως για την παραγωγη ενος φαρμακου για την αγωγη οφθαλμικων διαταραχων |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060257486A1 (enExample) |
| EP (1) | EP1906916B1 (enExample) |
| JP (1) | JP4968955B2 (enExample) |
| KR (1) | KR20080011311A (enExample) |
| CN (1) | CN101175476B (enExample) |
| AT (1) | ATE412402T1 (enExample) |
| AU (1) | AU2006244245B2 (enExample) |
| BR (1) | BRPI0608774A2 (enExample) |
| CA (1) | CA2607014A1 (enExample) |
| CY (1) | CY1108676T1 (enExample) |
| DE (1) | DE602006003438D1 (enExample) |
| DK (1) | DK1906916T3 (enExample) |
| ES (1) | ES2313670T3 (enExample) |
| MX (1) | MX2007014084A (enExample) |
| PL (1) | PL1906916T3 (enExample) |
| PT (1) | PT1906916E (enExample) |
| SI (1) | SI1906916T1 (enExample) |
| WO (1) | WO2006121964A2 (enExample) |
| ZA (1) | ZA200709296B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1885336T1 (sl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj |
| TW200812575A (en) * | 2006-04-28 | 2008-03-16 | Alcon Inc | Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye |
| TW201023912A (en) | 2008-12-05 | 2010-07-01 | Alcon Res Ltd | Pharmaceutical suspension |
| US8912236B2 (en) * | 2009-03-03 | 2014-12-16 | Alcon Research, Ltd. | Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye |
| CN105362221A (zh) * | 2009-03-03 | 2016-03-02 | 爱尔康研究有限公司 | 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物 |
| HUE038821T2 (hu) * | 2009-12-03 | 2018-11-28 | Novartis Ag | Karboxivinil polimert tartalmazó nanorészecske szuszpenziók |
| WO2011071995A2 (en) | 2009-12-08 | 2011-06-16 | Case Western Reserve University | Compounds and methods of treating ocular disorders |
| CN103079595B (zh) * | 2010-08-27 | 2015-11-25 | 若素制药株式会社 | 滴眼用水性组合物 |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| CN104706579A (zh) * | 2015-03-12 | 2015-06-17 | 广州仁恒医药科技有限公司 | 一种夫西地酸滴眼液及其制备方法 |
| CN111285845B (zh) * | 2020-02-11 | 2021-01-01 | 深圳厚存纳米药业有限公司 | 末端官能团化的泊洛沙胺衍生物 |
| US12049606B2 (en) * | 2021-01-12 | 2024-07-30 | Johnson & Johnson Vision Care, Inc. | Compositions for ophthalmologic devices |
| CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
| US12102622B2 (en) * | 2021-02-10 | 2024-10-01 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| US12263160B2 (en) | 2021-09-22 | 2025-04-01 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| IL319352A (en) * | 2022-09-15 | 2025-05-01 | Arcutis Biotherapeutics Inc | Pharmaceutical preparations of roflumilast and solvents capable of dissolving high amounts of the drug |
| CN118032955A (zh) * | 2022-11-14 | 2024-05-14 | 上海方予健康医药科技有限公司 | 一种制剂中表面活性剂含量的测定方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4313949A (en) * | 1979-09-26 | 1982-02-02 | A. H. Robins Company, Inc. | Method of producing an inhibitory effect on blood platelet aggregation |
| EP0348527B1 (en) * | 1987-12-25 | 1993-06-23 | Santen Pharmaceutical Co., Ltd. | Antiallergic eye drop |
| US4910225A (en) * | 1988-01-27 | 1990-03-20 | Senju Pharmaceutical Co., Ltd. | Locally administrable therapeutic composition for inflammatory disease |
| US5521222A (en) * | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5461081A (en) * | 1989-09-28 | 1995-10-24 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| US5369095A (en) * | 1990-02-14 | 1994-11-29 | Alcon Laboratories, Inc. | Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers |
| US5631005A (en) * | 1994-09-21 | 1997-05-20 | Alcon Laboratories, Inc. | Use of amidoamines in ophthalmic compositions |
| US5631004A (en) * | 1993-09-30 | 1997-05-20 | Alcon Laboratories, Inc. | Use of sustained release antibiotic compositions in ophthalmic surgical procedures |
| US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
| US5475034A (en) * | 1994-06-06 | 1995-12-12 | Alcon Laboratories, Inc. | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
| JPH10158188A (ja) * | 1996-11-29 | 1998-06-16 | Senju Pharmaceut Co Ltd | 角膜治療用組成物 |
| BR9806123A (pt) * | 1997-07-29 | 1999-08-31 | Alcon Lab Inc | Soluções condicionantes para cuidado de lente de contato dura |
| US6037328A (en) * | 1998-12-22 | 2000-03-14 | Bausch & Lomb Incorporated | Method and composition for rewetting and preventing deposits on contact lens |
| US6482799B1 (en) * | 1999-05-25 | 2002-11-19 | The Regents Of The University Of California | Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial |
| IT1313610B1 (it) * | 1999-08-09 | 2002-09-09 | S I F I Societa Ind Farmaceuti | Processo per la preparazione di formulazioni acquose per uso oftalmico |
| US6582724B2 (en) * | 1999-12-16 | 2003-06-24 | Dermatrends, Inc. | Dual enhancer composition for topical and transdermal drug delivery |
| EP1249249A1 (en) * | 2000-12-12 | 2002-10-16 | Menicon Co., Ltd. | Ophthalmic composition |
| AR030346A1 (es) * | 2000-08-14 | 2003-08-20 | Alcon Inc | Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico |
| AR031135A1 (es) * | 2000-10-10 | 2003-09-10 | Upjohn Co | Composiciones de antibiotico topico para el tratamiento de infecciones oculares |
| US20020115578A1 (en) * | 2000-12-14 | 2002-08-22 | Groemminger Suzanne F. | Composition for cleaning and wetting contact lenses |
| US6646003B2 (en) * | 2001-04-02 | 2003-11-11 | Alcon, Inc. | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac |
| JP2003137775A (ja) * | 2001-10-31 | 2003-05-14 | Menicon Co Ltd | 眼科用組成物 |
| US20030133905A1 (en) * | 2001-12-20 | 2003-07-17 | Zhenze Hu | Composition for treating contact lenses in the eye |
| US6765001B2 (en) * | 2001-12-21 | 2004-07-20 | Medicis Pharmaceutical Corporation | Compositions and methods for enhancing corticosteroid delivery |
| US7119112B2 (en) * | 2002-02-28 | 2006-10-10 | Icagen, Inc. | Sulfonamides as potassium channel blockers |
| AU2003217810C9 (en) * | 2002-02-28 | 2008-06-12 | Icagen, Inc. | Methods for treating diseases related to intraocular pressure |
| US20040115270A1 (en) * | 2002-12-13 | 2004-06-17 | Dharmendra Jani | Absorption and controlled release of polyethers from hydrogel biomaterials |
| JPWO2004084877A1 (ja) * | 2003-03-26 | 2006-06-29 | 株式会社メニコン | 眼科用組成物 |
| TWI358290B (en) * | 2004-12-02 | 2012-02-21 | Alcon Inc | Topical nepafenac formulations |
| SI1885336T1 (sl) * | 2005-05-10 | 2009-08-31 | Alcon Inc | Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj |
-
2006
- 2006-05-08 AU AU2006244245A patent/AU2006244245B2/en not_active Ceased
- 2006-05-08 CN CN200680016190XA patent/CN101175476B/zh not_active Expired - Fee Related
- 2006-05-08 DE DE602006003438T patent/DE602006003438D1/de not_active Expired - Lifetime
- 2006-05-08 US US11/429,736 patent/US20060257486A1/en not_active Abandoned
- 2006-05-08 EP EP06759259A patent/EP1906916B1/en not_active Expired - Lifetime
- 2006-05-08 WO PCT/US2006/017607 patent/WO2006121964A2/en not_active Ceased
- 2006-05-08 JP JP2008511215A patent/JP4968955B2/ja not_active Expired - Fee Related
- 2006-05-08 PL PL06759259T patent/PL1906916T3/pl unknown
- 2006-05-08 BR BRPI0608774-4A patent/BRPI0608774A2/pt not_active IP Right Cessation
- 2006-05-08 PT PT06759259T patent/PT1906916E/pt unknown
- 2006-05-08 ZA ZA200709296A patent/ZA200709296B/xx unknown
- 2006-05-08 DK DK06759259T patent/DK1906916T3/da active
- 2006-05-08 MX MX2007014084A patent/MX2007014084A/es active IP Right Grant
- 2006-05-08 SI SI200630144T patent/SI1906916T1/sl unknown
- 2006-05-08 AT AT06759259T patent/ATE412402T1/de active
- 2006-05-08 KR KR1020077027978A patent/KR20080011311A/ko not_active Ceased
- 2006-05-08 ES ES06759259T patent/ES2313670T3/es not_active Expired - Lifetime
- 2006-05-08 CA CA002607014A patent/CA2607014A1/en not_active Abandoned
-
2008
- 2008-12-10 CY CY20081101427T patent/CY1108676T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ATE412402T1 (de) | 2008-11-15 |
| PL1906916T3 (pl) | 2009-02-27 |
| KR20080011311A (ko) | 2008-02-01 |
| AU2006244245B2 (en) | 2010-11-18 |
| JP2008540533A (ja) | 2008-11-20 |
| CN101175476A (zh) | 2008-05-07 |
| ZA200709296B (en) | 2009-01-28 |
| WO2006121964A3 (en) | 2007-03-22 |
| AU2006244245A1 (en) | 2006-11-16 |
| CN101175476B (zh) | 2011-11-16 |
| ES2313670T3 (es) | 2009-03-01 |
| CA2607014A1 (en) | 2006-11-16 |
| PT1906916E (pt) | 2008-12-10 |
| WO2006121964A2 (en) | 2006-11-16 |
| DE602006003438D1 (de) | 2008-12-11 |
| EP1906916B1 (en) | 2008-10-29 |
| DK1906916T3 (da) | 2009-01-19 |
| US20060257486A1 (en) | 2006-11-16 |
| SI1906916T1 (sl) | 2009-02-28 |
| JP4968955B2 (ja) | 2012-07-04 |
| BRPI0608774A2 (pt) | 2010-01-26 |
| EP1906916A2 (en) | 2008-04-09 |
| MX2007014084A (es) | 2008-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200709251B (en) | Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders | |
| WO2020016659A3 (en) | Multiparticulate formulations of cannabinoids | |
| NO20075660L (no) | Blanding for behandling av inflammatoriske sykdommer | |
| ZA200709296B (en) | Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders | |
| CY1119248T1 (el) | 5-υποκατεστημενα παραγωγα κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| PA8680701A1 (es) | Derivados de oxindol | |
| MXPA05012573A (es) | Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa. | |
| BRPI0509863A (pt) | liberação de fármaco para fundo de olho | |
| ECSP066972A (es) | Profármacos mutuos de glucosamina y glucosamina/anti-inflamatorio, composiciones, y métodos | |
| DK1689724T3 (da) | Quinazolinonforbindelser som anticancermidler | |
| BRPI0416752B8 (pt) | composição farmacêutica, uso de um ou mais compostos, e, compostos | |
| UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| SE0101932D0 (sv) | Pharmaceutical combinations | |
| BRPI0812494A2 (pt) | Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo | |
| UY27275A1 (es) | Composiciones y metodos para aumentar la biodisponibilidad de agentes farmacéuticos | |
| BRPI0510778B8 (pt) | composição farmacêutica, processo para preparação da :mesma, e, uso de uma composição | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| WO2007077203A3 (en) | Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases | |
| DK1814848T3 (da) | 2,3,4-substitueret-cyclopentanoner som terapeutiske midler | |
| JOP20190054B1 (ar) | مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
| CR9074A (es) | Agente para la profilaxis o tratamiento del sindrome metabolico | |
| ECSP088236A (es) | Formas y composiciones de dosificaciones farmacéuticas | |
| TW200736220A (en) | Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents | |
| DE60233647D1 (de) | Reduziertes vitamin b2 enthaltende arzneimittel |